Валеология: Здоровье, Болезнь, Выздоровление. 2020; : 47-51
КОПЕПТИН В РАННЕЙ ДИАГНОСТИКЕ ИНФАРКТА МИОКАРДА У ПАЦИЕНТОВ С ОСТРЫМ КОРОНАРНЫМ СИНДРОМОМ
Аннотация
В литературном обзоре представлены результаты исследований, изучающих копептин в качестве биомаркера некроза миокарда, возможность использовать копептин как средство ранней диагностики и исключения инфаркта миокарда. Копептин демонстрирует реакцию эндогенного нейрогормонального стресса, происходит увеличение концетрации в крови уже в 1 час ИМ и уменьшается к 10 часу от начала индексного события. Отсутствие копептина и тропонина Т достоверно позволяет исключить ИМ. Уровень увеличения копептина имеет зависимость от размеров очага некроза миокарда и характеризует дальнейший прогноз заболевания: риск развития смерти и прогрессирования хронической сердечной недостаточности. Объектами исследования явились литературные источники по вопросам исследования копептина. Ключевой момент всех исследований состоит в том что остается недостаточно открытым и понятным тот конкретный период времени, в течении которого нужно определять копептин у пациентов с ОКС. Также, выполненные по сей день работы еще не дали какой-либо информации о возможности применения копептина для лечения больных ИМ с целью улучшения прогноза. Актуальный вопрос остается открытым и требует дальнейших исследований.
Список литературы
1. Campbell R. Myocardial infarction: International guidelines. M.: 1997; 87 p. (In russ.) / Kэмпбелл Р. Международное руководство по инфаркту миокарда. – М., 1997. – 87 c.
2. Сhambless L., Keil U., Dobson A., et al. Population versus clinical view of case fatality from acute coronary heart disease: results from WHo MoNICA 1985-1990. Circulation 1997; 96: 3849-59.
3. Kesov P G., Shalaev S. V. Risk factors, clinical manifestations, and especially the treatment of acute coronary syndrome from the standpoint of the gender perspective. Meducal science and education of Ural 2015;16 (2): 164-8.
4. Тhygesen K., Alpert J. S., Jaffe A. S., et al. third Universal definition of Myocardial Infarction. Circulation 2012; 126 (16): 2020-35.
5. Тhygesen K., Mair J., giannitsis e, et al. How to Use High — Sensititity Cardiac troponins in Acute Cardiac Care. Eur Heart J 2012; 33 (18): 2252-7.
6. Jobs A., Thiele H. eSC guidelines 2015: Non-St-elevation acute coronary Syndrome. Herz 2015; 40 (8) 1027-33.
7. Preibisz J. J., Sealey J. E., Laragh J. H., et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: 1129-38.
8. Kokorin V. A., Luyson V. A., Shaiduyk O. Y. Increased activity neurohumoral systems of myocardial infarction patients: prognostic importance. Scientific records sevics of Medicine. Pharmacy 2011; (105): 37-43.
9. Reichlin T., Hochholzer W., Stelzig C., et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54 (1): 60-8.
10. Gu Y. L., Voors A. A., Zijlstra F., et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin res Cardiol 2011; 100 (12): 1069-76.
11. Ananth V., Beig J. R., Tramboo N., et al. Does plasma copeptin level at admission predict final infarct size in St – elevation myocardial infarction. International J of Cardiology 2016; 219: 326-30.
12. Afzali D.,Erren M.,Pavenstadt H.-J., et al.Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin research in Cardiology 2013; 102: 755-63.
13. Folli Ch., Consonni D., Spessot M., et al. Diagnostic rolle of copeptin in patients presenting with chest pain in the emergency room. eur J of Internal Medicine 2013; 24 (2): 189-93.
14. Sayed Z. H., Mahmoud H. A., el Shall L. Y., et al. Impact of copeptin on diagnosis of acute coronary syndrome egyptian J of Medical Human genetics 2014; 15 (3): 241-7.
15. Liorens P., Sanchez M., Herrero P., et al. the utility of copeptin in the emergency department for non — St-elevation myocardial infarction rapid rule out: Co Ped-MIrro study. eur J emerg Med 2014; 21 (3): 220-9.
Valeology: Health - Illnes - recovery. 2020; : 47-51
COPEPTIN IN EARLY DIAGNOSIS OF MYOCARDIAL INFARCTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
Abstract
The literature review presents the results of studies examining copeptin as a biomarker of myocardial necrosis and the possibility of using copeptin as a means of early diagnosis and exclusion of myocardial infarction. Copeptin demonstrates the reaction of endogenous neurohormonal stress, there is an increase in blood concentration as early as 1 hour of MI and decreases by 10 hours from the beginning of the index event. The absence of copeptin and troponin T can reliably exclude MI. The level of increase in copeptin depends on the size of the focus of myocardial necrosis and characterizes the further prognosis of the disease: the risk of death and progression of chronic heart failure. Object of study: Literary sources on the research of copeptin. The key point of all studies is that the specific period of time during which it is necessary to determine copeptin in patients with ACS remains insufficiently open and understandable. Also, the work performed to this day has not yet provided any information about the possibility of using copeptin for the treatment of patients with MI in order to improve the prognosis. The actual question remains open and requires further research.
References
1. Campbell R. Myocardial infarction: International guidelines. M.: 1997; 87 p. (In russ.) / Kempbell R. Mezhdunarodnoe rukovodstvo po infarktu miokarda. – M., 1997. – 87 c.
2. Shambless L., Keil U., Dobson A., et al. Population versus clinical view of case fatality from acute coronary heart disease: results from WHo MoNICA 1985-1990. Circulation 1997; 96: 3849-59.
3. Kesov P G., Shalaev S. V. Risk factors, clinical manifestations, and especially the treatment of acute coronary syndrome from the standpoint of the gender perspective. Meducal science and education of Ural 2015;16 (2): 164-8.
4. Thygesen K., Alpert J. S., Jaffe A. S., et al. third Universal definition of Myocardial Infarction. Circulation 2012; 126 (16): 2020-35.
5. Thygesen K., Mair J., giannitsis e, et al. How to Use High — Sensititity Cardiac troponins in Acute Cardiac Care. Eur Heart J 2012; 33 (18): 2252-7.
6. Jobs A., Thiele H. eSC guidelines 2015: Non-St-elevation acute coronary Syndrome. Herz 2015; 40 (8) 1027-33.
7. Preibisz J. J., Sealey J. E., Laragh J. H., et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: 1129-38.
8. Kokorin V. A., Luyson V. A., Shaiduyk O. Y. Increased activity neurohumoral systems of myocardial infarction patients: prognostic importance. Scientific records sevics of Medicine. Pharmacy 2011; (105): 37-43.
9. Reichlin T., Hochholzer W., Stelzig C., et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol 2009; 54 (1): 60-8.
10. Gu Y. L., Voors A. A., Zijlstra F., et al. Comparison of the temporal release pattern of copeptin with conventional biomarkers in acute myocardial infarction. Clin res Cardiol 2011; 100 (12): 1069-76.
11. Ananth V., Beig J. R., Tramboo N., et al. Does plasma copeptin level at admission predict final infarct size in St – elevation myocardial infarction. International J of Cardiology 2016; 219: 326-30.
12. Afzali D.,Erren M.,Pavenstadt H.-J., et al.Impact of copeptin on diagnosis, risk stratification, and intermediate-term prognosis of acute coronary syndromes. Clin research in Cardiology 2013; 102: 755-63.
13. Folli Ch., Consonni D., Spessot M., et al. Diagnostic rolle of copeptin in patients presenting with chest pain in the emergency room. eur J of Internal Medicine 2013; 24 (2): 189-93.
14. Sayed Z. H., Mahmoud H. A., el Shall L. Y., et al. Impact of copeptin on diagnosis of acute coronary syndrome egyptian J of Medical Human genetics 2014; 15 (3): 241-7.
15. Liorens P., Sanchez M., Herrero P., et al. the utility of copeptin in the emergency department for non — St-elevation myocardial infarction rapid rule out: Co Ped-MIrro study. eur J emerg Med 2014; 21 (3): 220-9.
